{"title":"治疗类风湿关节炎的靶向途径和综合方法","authors":"Shradha Devi Dwivedi, Krishna Yadav, Anita Bhoi, Keshav Kant Sahu, Neelam Sangwan, Deependra Singh, Manju Singh","doi":"10.1615/critrevtherdrugcarriersyst.2023044719","DOIUrl":null,"url":null,"abstract":"Rheumatoid arthritis (RA) is a chronic symmetrical systemic disorder that not only affects joints but also other organs such as heart, lungs, kidney, and liver. Approximately there is 0.5% -1% of the total population affected by rheumatoid arthritis. RA pathogenesis still remains unclear due to which its appropriate treatment is a challenge. Further, multitudes of factors have been reported to affect its progression i.e. genetic factor, environmental factor, immune factor, and oxidative factor. Therapeutic approaches available for the treatment of RA include NSAIDs, DMARDs, enzymatic, hormonal, and gene therapies. But most of them provide the symptomatic relief without treating the core of the disease. This makes it obligatory to explore and reach the molecular targets for cure and long term relief from rheumatoid arthritis. Herein, we attempt to provide extensive overlay of the new targets for RA treatment such as signalling pathways, proteins, and receptors affecting the progression of the disease and its severity. Precise modification in these targets such as suppressing the notch signalling pathway, SIRT 3 protein, Sphingosine-1-phosphate receptor and stimulating the neuronal signals particularly efferent vagus nerve and SIRT 1 protein may offer long term relief and potentially diminish the chronicity. To target or alter the novel molecules and signaling pathway a specific delivery system is required such as liposome, nanoparticles and micelles and many more. In these review paper we have discuss about novel targets and delivery system for treating RA.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Targeting pathways and integrated approaches to treat Rheumatoid Arthritis\",\"authors\":\"Shradha Devi Dwivedi, Krishna Yadav, Anita Bhoi, Keshav Kant Sahu, Neelam Sangwan, Deependra Singh, Manju Singh\",\"doi\":\"10.1615/critrevtherdrugcarriersyst.2023044719\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rheumatoid arthritis (RA) is a chronic symmetrical systemic disorder that not only affects joints but also other organs such as heart, lungs, kidney, and liver. Approximately there is 0.5% -1% of the total population affected by rheumatoid arthritis. RA pathogenesis still remains unclear due to which its appropriate treatment is a challenge. Further, multitudes of factors have been reported to affect its progression i.e. genetic factor, environmental factor, immune factor, and oxidative factor. Therapeutic approaches available for the treatment of RA include NSAIDs, DMARDs, enzymatic, hormonal, and gene therapies. But most of them provide the symptomatic relief without treating the core of the disease. This makes it obligatory to explore and reach the molecular targets for cure and long term relief from rheumatoid arthritis. Herein, we attempt to provide extensive overlay of the new targets for RA treatment such as signalling pathways, proteins, and receptors affecting the progression of the disease and its severity. Precise modification in these targets such as suppressing the notch signalling pathway, SIRT 3 protein, Sphingosine-1-phosphate receptor and stimulating the neuronal signals particularly efferent vagus nerve and SIRT 1 protein may offer long term relief and potentially diminish the chronicity. To target or alter the novel molecules and signaling pathway a specific delivery system is required such as liposome, nanoparticles and micelles and many more. In these review paper we have discuss about novel targets and delivery system for treating RA.\",\"PeriodicalId\":50614,\"journal\":{\"name\":\"Critical Reviews in Therapeutic Drug Carrier Systems\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical Reviews in Therapeutic Drug Carrier Systems\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1615/critrevtherdrugcarriersyst.2023044719\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Therapeutic Drug Carrier Systems","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2023044719","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Targeting pathways and integrated approaches to treat Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic symmetrical systemic disorder that not only affects joints but also other organs such as heart, lungs, kidney, and liver. Approximately there is 0.5% -1% of the total population affected by rheumatoid arthritis. RA pathogenesis still remains unclear due to which its appropriate treatment is a challenge. Further, multitudes of factors have been reported to affect its progression i.e. genetic factor, environmental factor, immune factor, and oxidative factor. Therapeutic approaches available for the treatment of RA include NSAIDs, DMARDs, enzymatic, hormonal, and gene therapies. But most of them provide the symptomatic relief without treating the core of the disease. This makes it obligatory to explore and reach the molecular targets for cure and long term relief from rheumatoid arthritis. Herein, we attempt to provide extensive overlay of the new targets for RA treatment such as signalling pathways, proteins, and receptors affecting the progression of the disease and its severity. Precise modification in these targets such as suppressing the notch signalling pathway, SIRT 3 protein, Sphingosine-1-phosphate receptor and stimulating the neuronal signals particularly efferent vagus nerve and SIRT 1 protein may offer long term relief and potentially diminish the chronicity. To target or alter the novel molecules and signaling pathway a specific delivery system is required such as liposome, nanoparticles and micelles and many more. In these review paper we have discuss about novel targets and delivery system for treating RA.
期刊介绍:
Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields.
Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly difficult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.